Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Top advances of the year: Melanoma.
Khattak MA, Luke JJ. Khattak MA, et al. Among authors: luke jj. Cancer. 2024 Apr 29. doi: 10.1002/cncr.35354. Online ahead of print. Cancer. 2024. PMID: 38682653 No abstract available.
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial.
Luke JJ, Rutkowski P, Queirolo P, Del Vecchio M, Mackiewicz J, Chiarion-Sileni V, de la Cruz Merino L, Khattak MA, Schadendorf D, Long GV, Ascierto PA, Mandala M, De Galitiis F, Haydon A, Dummer R, Grob JJ, Robert C, Carlino MS, Mohr P, Poklepovic A, Sondak VK, Scolyer RA, Kirkwood JM, Chen K, Diede SJ, Ahsan S, Ibrahim N, Eggermont AMM; KEYNOTE-716 Investigators. Luke JJ, et al. Lancet. 2022 Apr 30;399(10336):1718-1729. doi: 10.1016/S0140-6736(22)00562-1. Epub 2022 Apr 1. Lancet. 2022. PMID: 35367007 Clinical Trial.
Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
Khattak MA, Luke JJ, Long GV, Ascierto PA, Rutkowski P, Schadendorf D, Robert C, Grob JJ, de la Cruz Merino L, Del Vecchio M, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Carlino MS, Mohr P, De Galitiis F, Ross MI, Eroglu Z, Chen K, Jiang R, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Kirkwood JM. Khattak MA, et al. Among authors: luke jj. Eur J Cancer. 2022 Nov;176:207-217. doi: 10.1016/j.ejca.2022.08.004. Epub 2022 Oct 3. Eur J Cancer. 2022. PMID: 36202690 Free article. Clinical Trial.
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
Long GV, Luke JJ, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Mohr P, Dummer R, Gershenwald JE, Yoon CH, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Ascierto PA; KEYNOTE-716 Investigators. Long GV, et al. Among authors: luke jj. Lancet Oncol. 2022 Nov;23(11):1378-1388. doi: 10.1016/S1470-2045(22)00559-9. Epub 2022 Oct 18. Lancet Oncol. 2022. PMID: 36265502 Clinical Trial.
Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
Luke JJ, Ascierto PA, Khattak MA, de la Cruz Merino L, Del Vecchio M, Rutkowski P, Spagnolo F, Mackiewicz J, Chiarion-Sileni V, Kirkwood JM, Robert C, Grob JJ, de Galitiis F, Schadendorf D, Carlino MS, Wu XL, Fukunaga-Kalabis M, Krepler C, Eggermont AMM, Long GV. Luke JJ, et al. J Clin Oncol. 2024 May 10;42(14):1619-1624. doi: 10.1200/JCO.23.02355. Epub 2024 Mar 7. J Clin Oncol. 2024. PMID: 38452313 Free PMC article. Clinical Trial.
Top advances of the year: Melanoma.
Augustin RC, Luke JJ. Augustin RC, et al. Among authors: luke jj. Cancer. 2023 Mar 15;129(6):822-828. doi: 10.1002/cncr.34590. Epub 2023 Jan 11. Cancer. 2023. PMID: 36629350 Free article. No abstract available.
Considering adjuvant therapy for stage II melanoma.
Poklepovic AS, Luke JJ. Poklepovic AS, et al. Among authors: luke jj. Cancer. 2020 Mar 15;126(6):1166-1174. doi: 10.1002/cncr.32585. Epub 2019 Dec 23. Cancer. 2020. PMID: 31869447 Free PMC article. Review.
Potential of circulating tumor DNA to refine immunotherapy.
Lee RJ, Luke JJ. Lee RJ, et al. Among authors: luke jj. Cancer. 2023 Jun 1;129(11):1646-1648. doi: 10.1002/cncr.34714. Epub 2023 Mar 4. Cancer. 2023. PMID: 36869645 Free PMC article. No abstract available.
Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
Schadendorf D, Luke JJ, Ascierto PA, Long GV, Rutkowski P, Khattak A, Del Vecchio M, de la Cruz-Merino L, Mackiewicz J, Sileni VC, Kirkwood JM, Robert C, Grob JJ, Dummer R, Carlino MS, Zhao Y, Kalabis M, Krepler C, Eggermont A, Scolyer RA. Schadendorf D, et al. Among authors: luke jj. J Immunother Cancer. 2024 Mar 13;12(3):e007501. doi: 10.1136/jitc-2023-007501. J Immunother Cancer. 2024. PMID: 38485189 Free PMC article. Clinical Trial.
Identification of tumor-intrinsic drivers of immune exclusion in acral melanoma.
Augustin RC, Newman S, Li A, Joy M, Lyons M, Pham MP, Lucas P, Smith K, Sander C, Isett B, Davar D, Najjar YG, Zarour HM, Kirkwood JM, Luke JJ, Bao R. Augustin RC, et al. Among authors: luke jj. J Immunother Cancer. 2023 Oct;11(10):e007567. doi: 10.1136/jitc-2023-007567. J Immunother Cancer. 2023. PMID: 37857525 Free PMC article.
198 results